Canada
· Delayed Price · Currency is CAD ZYUS Life Sciences Statistics
Total Valuation
ZYUS Life Sciences has a market cap or net worth of CAD 61.72 million. The enterprise value is 69.31 million.
| Market Cap | 61.72M |
| Enterprise Value | 69.31M |
Important Dates
The next estimated earnings date is Thursday, May 8, 2025.
| Earnings Date | May 8, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
ZYUS Life Sciences has 74.36 million shares outstanding. The number of shares has increased by 47.13% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 74.36M |
| Shares Change (YoY) | +47.13% |
| Shares Change (QoQ) | +1.88% |
| Owned by Insiders (%) | 53.75% |
| Owned by Institutions (%) | 0.21% |
| Float | 32.40M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 130.36 |
| PB Ratio | 4.15 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -1.90 |
| EV / Sales | 153.34 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -9.09 |
Financial Position
The company has a current ratio of 0.24, with a Debt / Equity ratio of 0.53.
| Current Ratio | 0.24 |
| Quick Ratio | 0.05 |
| Debt / Equity | 0.53 |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.04 |
| Interest Coverage | -33.88 |
Financial Efficiency
Return on equity (ROE) is -118.64% and return on invested capital (ROIC) is -29.38%.
| Return on Equity (ROE) | -118.64% |
| Return on Assets (ROA) | -22.33% |
| Return on Capital (ROIC) | -29.38% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.01 |
| Inventory Turnover | 0.80 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -8.79% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -8.79% |
| 50-Day Moving Average | 0.83 |
| 200-Day Moving Average | 0.95 |
| Relative Strength Index (RSI) | 45.24 |
| Average Volume (20 Days) | 3,135 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, ZYUS Life Sciences had revenue of CAD 452,000 and -36.55 million in losses. Loss per share was -0.52.
| Revenue | 452,000 |
| Gross Profit | -1.93M |
| Operating Income | -18.91M |
| Pretax Income | -42.39M |
| Net Income | -36.55M |
| EBITDA | -16.33M |
| EBIT | -18.91M |
| Loss Per Share | -0.52 |
Balance Sheet
The company has 346,000 in cash and 7.94 million in debt, giving a net cash position of -7.60 million or -0.10 per share.
| Cash & Cash Equivalents | 346,000 |
| Total Debt | 7.94M |
| Net Cash | -7.60M |
| Net Cash Per Share | -0.10 |
| Equity (Book Value) | 14.89M |
| Book Value Per Share | 0.20 |
| Working Capital | -10.82M |
Cash Flow
In the last 12 months, operating cash flow was -7.39 million and capital expenditures -237,000, giving a free cash flow of -7.63 million.
| Operating Cash Flow | -7.39M |
| Capital Expenditures | -237,000 |
| Free Cash Flow | -7.63M |
| FCF Per Share | -0.10 |
Margins
| Gross Margin | n/a |
| Operating Margin | -4,182.52% |
| Pretax Margin | -9,379.20% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ZYUS Life Sciences does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -47.13% |
| Shareholder Yield | -47.13% |
| Earnings Yield | -62.38% |
| FCF Yield | -12.36% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
ZYUS Life Sciences has an Altman Z-Score of -6.32. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -6.32 |
| Piotroski F-Score | n/a |